60 Degrees Pharmaceuticals, Inc.
SXTPHealthcareNASDAQBiotechnology
Scan Results
Daily timeframe60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the. Valued at $3.4M, SXTP is a micro-cap name in its sector. It offers Arakoda for malaria prevention treatment.
Market Cap
$3.4M
Beta
2.54
P/E (TTM)
—
P/E (Fwd)
-0.27
EPS (TTM)
$-2.67
EPS (Fwd)
$-3.58
ROE
-332.9%
ROA
-127.1%
Cash
$1.0M
Total Debt
$151,179
Free CF
-$6.1M
52W Change
-83.9%
Annual Financials
Cash vs Debt
Where SXTP stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SXTP finished 49.20% below its 150-day moving average ($1.87) and 57.40% below its 200-day moving average ($2.23). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SXTP overbought or oversold?
At the September 3, 2026 close, SXTP's RSI(14) was 29.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
60 Degrees Pharmaceuticals, Inc. holds $1.0M in cash against $151K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$6.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -332.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $223K (2022) to $1.0M (2025), reflecting a 350% increase over the period.
60 Degrees Pharmaceuticals, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing SXTP's risk profile alongside its fundamentals and technical indicators provides a more complete picture.